Compare Anheuser-Busch Inbev SA (BUD) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Koninklijke Philips NV — how do they compare? Anheuser-Busch Inbev SA trades at $79.64 (market cap $153.45B), while Koninklijke Philips NV trades at $27.02 (market cap $25.47B). The key difference: Anheuser-Busch Inbev SA is far larger — about 6× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BUD | PHG | |
|---|---|---|
Market Cap | $153.45B | $25.47B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $32.91 |
52-Week Low | $57.10 | $24.38 |
Enterprise Value | $214.64B | $31.74B |
Dividend Yield | 1.7% | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
PHG trades at $27.34, down 0.22% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operating cash flow of $1.17B. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships demonstrate innovation momentum.
The stock presents a mixed outlook with 41% analyst buy ratings but bearish technical indicators. Key opportunities include AI healthcare adoption and margin expansion, while risks involve competitive pressures and debt levels. Valuation appears reasonable with P/E of 24.01 and P/S of 1.31, but requires monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
